These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 31297337)

  • 21. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
    Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
    Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
    Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
    Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?
    Kahn RM; Gordhandas S; Maddy BP; Baltich Nelson B; Askin G; Christos PJ; Caputo TA; Chapman-Davis E; Holcomb K; Frey MK
    Cancer; 2019 Sep; 125(18):3172-3183. PubMed ID: 31150123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implication of DNA repair genes in Lynch-like syndrome.
    Xicola RM; Clark JR; Carroll T; Alvikas J; Marwaha P; Regan MR; Lopez-Giraldez F; Choi J; Emmadi R; Alagiozian-Angelova V; Kupfer SS; Ellis NA; Llor X
    Fam Cancer; 2019 Jul; 18(3):331-342. PubMed ID: 30989425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome.
    Engel C; Ahadova A; Seppälä TT; Aretz S; Bigirwamungu-Bargeman M; Bläker H; Bucksch K; Büttner R; de Vos Tot Nederveen Cappel WT; Endris V; Holinski-Feder E; Holzapfel S; Hüneburg R; Jacobs MAJM; Koornstra JJ; Langers AM; Lepistö A; Morak M; Möslein G; Peltomäki P; Pylvänäinen K; Rahner N; Renkonen-Sinisalo L; Schulmann K; Steinke-Lange V; Stenzinger A; Strassburg CP; van de Meeberg PC; van Kouwen M; van Leerdam M; Vangala DB; Vecht J; Verhulst ML; von Knebel Doeberitz M; Weitz J; Zachariae S; Loeffler M; Mecklin JP; Kloor M; Vasen HF; ;
    Gastroenterology; 2020 Apr; 158(5):1326-1333. PubMed ID: 31926173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lynch Syndrome Germline Mutations in Breast Cancer: Next Generation Sequencing Case-Control Study of 1,263 Participants.
    Nikitin AG; Chudakova DA; Enikeev RF; Sakaeva D; Druzhkov M; Shigapova LH; Brovkina OI; Shagimardanova EI; Gusev OA; Gordiev MG
    Front Oncol; 2020; 10():666. PubMed ID: 32547938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer.
    Carethers JM; Stoffel EM
    World J Gastroenterol; 2015 Aug; 21(31):9253-61. PubMed ID: 26309352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A simplified two-marker immunohistochemistry strategy for Lynch syndrome screening in endometrial cancer patients.
    Aiob A; Kim YR; Kim K; Kim H; Kim YB; Kim DW; No JH; Seo SH; Suh DH; Park KU
    Obstet Gynecol Sci; 2023 Nov; 66(6):537-544. PubMed ID: 37839795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline
    Huang YC; Lin PC; Wu PY; Chen NS; Shen MR; Yeh YM; Cheng YM
    Gynecol Oncol Rep; 2024 Jun; 53():101381. PubMed ID: 38584802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens.
    Akbari MR; Zhang S; Cragun D; Lee JH; Coppola D; McLaughlin J; Risch HA; Rosen B; Shaw P; Sellers TA; Schildkraut J; Narod SA; Pal T
    Fam Cancer; 2017 Jul; 16(3):351-355. PubMed ID: 28176205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome.
    Schwartz CJ; da Silva EM; Marra A; Gazzo AM; Selenica P; Rai VK; Mandelker D; Pareja F; Misyura M; D'Alfonso TM; Brogi E; Drullinsky P; Razavi P; Robson ME; Drago JZ; Wen HY; Zhang L; Weigelt B; Shia J; Reis-Filho JS; Zhang H
    Clin Cancer Res; 2022 Jan; 28(2):404-413. PubMed ID: 34667028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for Lynch syndrome in young Saudi colorectal cancer patients using microsatellite instability testing and next generation sequencing.
    Alqahtani M; Edwards C; Buzzacott N; Carpenter K; Alsaleh K; Alsheikh A; Abozeed W; Mashhour M; Almousa A; Housawi Y; Al Hawwaj S; Iacopetta B
    Fam Cancer; 2018 Apr; 17(2):197-203. PubMed ID: 28643016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sporadic endometrial adenocarcinoma with MMR deficiency due to biallelic MSH2 somatic mutations.
    Buecher B; De Pauw A; Bazire L; Houdayer C; Fievet A; Moncoutier V; Farkhondeh F; Melaabi S; Lyonnet DS; Golmard L
    Fam Cancer; 2018 Apr; 17(2):281-285. PubMed ID: 28819700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prevalence of lynch syndrome (DNA mismatch repair protein deficiency) in patients with primary localized prostate cancer using immunohistochemistry screening.
    Oka S; Urakami S; Hagiwara K; Hayashida M; Sakaguchi K; Miura Y; Inoshita N; Arai M
    Hered Cancer Clin Pract; 2023 Oct; 21(1):20. PubMed ID: 37828628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lynch-like Syndrome: Potential Mechanisms and Management.
    Martínez-Roca A; Giner-Calabuig M; Murcia O; Castillejo A; Soto JL; García-Heredia A; Jover R
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer.
    Caldés T; Godino J; Sanchez A; Corbacho C; De la Hoya M; Lopez Asenjo J; Saez C; Sanz J; Benito M; Ramon Y Cajal S; Diaz-Rubio E
    Oncol Rep; 2004 Sep; 12(3):621-9. PubMed ID: 15289847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
    Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
    Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive molecular assessment of mismatch repair deficiency in Lynch associated ovarian cancers using next generation sequencing panel.
    Kim SR; Oldfield L; Tone A; Pollett A; Pedersen S; Wellum J; Cesari M; Lajkosz K; Pugh TJ; Ferguson SE
    Int J Gynecol Cancer; 2024 Feb; 34(2):267-276. PubMed ID: 37940339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathologic features of endometrial cancer with mismatch repair deficiency.
    Gordhandas S; Kahn RM; Gamble C; Talukdar N; Maddy B; Baltich Nelson B; Askin G; Christos PJ; Holcomb K; Caputo TA; Chapman-Davis E; Frey MK
    Ecancermedicalscience; 2020; 14():1061. PubMed ID: 32582376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical problems of colorectal cancer and endometrial cancer cases with unknown cause of tumor mismatch repair deficiency (suspected Lynch syndrome).
    Buchanan DD; Rosty C; Clendenning M; Spurdle AB; Win AK
    Appl Clin Genet; 2014; 7():183-93. PubMed ID: 25328415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.